Opus Genetics (IRD) Accumulated Expenses (2019 - 2026)
Opus Genetics (IRD) posted quarterly Accumulated Expenses of $4.9 million for Q1 2026, up 854.95% year-over-year from $515000.0 in Q1 2025, and up 9.58% quarter-over-quarter from $4.5 million in Q4 2025.
Opus Genetics (IRD) Accumulated Expenses (2019 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Accumulated Expenses for 8 consecutive years, with $4.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses rose 854.95% year-over-year to $4.9 million; the TTM figure through Mar 2026 stood at $4.9 million (up 854.95% YoY), while the FY2025 annual figure was $4.5 million, down 44.91% from the prior year.
- Accumulated Expenses advanced to $4.9 million in Q1 2026 per IRD's latest filing, from $4.5 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $8.1 million in Q4 2024 and bottomed at $233000.0 in Q1 2023.
- Historically, Accumulated Expenses has averaged $2.5 million across 5 years, with a median of $1.4 million in 2022.
- Annual changes were most pronounced in 2024 — Accumulated Expenses jumped 1466.09% — and 2025, when it sank 85.89%.
- Opus Genetics' Accumulated Expenses stood at $782000.0 in 2022, then decreased by 3.71% to $753000.0 in 2023, then surged by 981.94% to $8.1 million in 2024, then slumped by 44.91% to $4.5 million in 2025, then rose by 9.58% to $4.9 million in 2026.
- Business Quant data shows IRD's Accumulated Expenses at $4.9 million in Q1 2026, $4.5 million in Q4 2025, and $1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.72 Mn |
| Mar 31, 2026 | 4.92 Mn |
| Dec 31, 2025 | 4.49 Mn |
| Sep 30, 2025 | 1.42 Mn |
| Jun 30, 2025 | 6.93 Mn |
| Mar 31, 2025 | 515,000.00 |
| Dec 31, 2024 | 8.15 Mn |
| Sep 30, 2024 | 410,000.00 |
| Jun 30, 2024 | 3.49 Mn |
| Mar 31, 2024 | 3.65 Mn |
| Dec 31, 2023 | 753,000.00 |
| Sep 30, 2023 | 1.93 Mn |
| Jun 30, 2023 | 300,000.00 |
| Mar 31, 2023 | 233,000.00 |
| Dec 31, 2022 | 782,000.00 |
| Sep 30, 2022 | 1.22 Mn |
| Jun 30, 2022 | 1.42 Mn |
| Mar 31, 2022 | 1.42 Mn |
| Dec 31, 2021 | 1.73 Mn |
| Sep 30, 2021 | 1.20 Mn |